Clinical Trials · NCT05296798

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Name: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: Hoffmann-La Roche
Enrollment: 922
Start date: Jul 2022
Locations: 202 sites, 29 countries
Primary endpoint: Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1

View Gonadorelin compound reference